Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as KSH01 injection
KSH01 · 1 trial · 1 indication
To evaluate the safety and tolerance of autologous TCR-T cells in target positive solid tumor subjects.
To preliminarily evaluate the objective remission rate of autologous TCR-T cells in the treatment of target positive solid tumor subjects (such as esophageal cancer, gastric cancer, head and neck cancer, bladder cancer, melanoma, sarcoma, etc.).
| Arm | Type | Description |
|---|---|---|
| TCR-T cells | EXPERIMENTAL | TCR-T cell injection |
| Name | Type | Description |
|---|---|---|
| KSH01 injection | DRUG | TCR-T cell injection |
Inclusion Criteria: * 1\) Voluntary participation in clinical research; Fully understand the study and voluntarily sign the informed consent form; Willing to follow and able to complete all test procedures; * 2\) Male or female, 18 to 70 years old (including boundary value); * 3\) Malignant solid t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
KSH01 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development and is being studied in patients with solid tumors. The drug is administered as an injection.
KSH01 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical trials for this investigational oncology drug.
KSH01 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy in patients with solid tumors.
KSH01 is being studied in a Phase 1 clinical trial with the identifier NCT05580796, titled 'KSH01-R02-101 Solid Tumors'. This trial is currently recruiting participants in China and aims to enroll 50 patients with solid tumors.
Yes, KSH01 is also known as KSH01 injection. The drug is administered as an injectable formulation, and both names refer to the same investigational oncology drug being developed for solid tumors.